National Study Launched to Understand the Prevalence of Lupus in the Cayman Islands

A landmark national study to estimate the prevalence of systemic lupus erythematosus (SLE) in the Cayman Islands is now underway marking the first research of its kind in the country and a significant step toward understanding the impact of this complex autoimmune disease within the local population.

Systemic lupus erythematosus (SLE), the most common and severe form of lupus, is a chronic condition that can affect multiple organs including the skin, joints, kidneys, and brain. Symptoms and signs such as fatigue, joint pain, mouth ulcers and rashes can fluctuate over time, often making the disease difficult to recognise and diagnose early.

Despite its serious health implications, there is currently limited national data on how many people in the Cayman Islands are living with SLE. Based on global estimates, between 20 and 90 individuals may be affected locally, with a midpoint estimate of approximately 40 people in a population of around 88,000. However, regional research from Barbados suggests prevalence may be significantly higher, indicating the need for accurate, localised data.

“This study is designed to generate a much-needed evidence base on the scale of SLE in our population,” said Dr. Sharon Chambers, Consultant Rheumatologist at Doctors Hospital and Chief Investigator.

“Reliable prevalence data is essential for healthcare planning, policy development, and improving awareness among both clinicians and the public.”

The study is recruiting individuals who had a diagnosis of SLE in 2024, whether newly diagnosed or previously known cases. In addition to estimating national prevalence, researchers will analyse clinical and demographic characteristics at diagnosis and compare two internationally recognised SLE classification systems.

This collaborative project brings together clinical and public health expertise from Doctors Hospital and the Cayman Islands Health Services Authority. Data analysis will be led by Rachel Corbett, National Epidemiologist at the Ministry of Health and Wellness.

Dr. Richard Preece, Medical Director at Doctors Hospital and Study Supervisor, added:

“The more we understand the impact of SLE in the Cayman Islands, the better we can target care and support. Medical research is central to delivering the high standard of care our patients deserve.”

Findings from the study are expected to support improved access to diagnosis, specialist care, and treatment, while also strengthening public and clinical awareness. The data will play a critical role in shaping healthcare policy, supporting advocacy efforts, and guiding future research initiatives aimed at improving outcomes for patients living with lupus.

Community awareness efforts are being supported by the Wings of Hope Lupus Warrior Support Group Cayman Islands.

Reshma Ragoonath, Founder of the group, said: “Having this study done on island helps us better understand how many people are living with lupus here. The data will be critical in shaping policy and improving access to treatments that can enhance quality of life. Lupus remains widely misunderstood, and this research is an important step toward greater awareness, empathy, and support for those affected.”

Ethical approval has been granted by the Health Services Authority Ethics Committee, and recruitment is currently ongoing.

Study Team Includes:

• Dr. Delroy Jefferson, Medical Director, Cayman Islands Health Services Authority

• Dr. Sharon Chambers, Consultant Rheumatologist, Doctors Hospital

• Dr. Santiago De Solo, Visiting Consultant Rheumatologist, HSA

• Dr. Schadé Stanton, Consultant Internal Medicine Physician, HSA

• Rachel Corbett, Ministry of Health and Wellness

• Diane Obana, Registered Nurse, Doctors Hospital